

Medgenics Announces Beta Thalassemia Research Program

Medgenics, Inc.
December 16, 2015 8:00 AM
[GlobeNewswire](#)



PHILADELPHIA,
Dec. 16, 2015
(GLOBE
NEWSWIRE) --
Medgenics, Inc.
(NYSE
MKT:MDGN),
today announced
the initiation of a
research program
to evaluate the

use of
TARGT_{EPO}TM
alone or in
combination with
iron restriction to
ameliorate
erythropoiesis in
Beta
Thalassemia
Intermedia (non-
transfusion
dependent
thalassemia or
NTDT) and Beta

Thalassemia
Major
(transfusion
dependent
thalassemia or
TDT). Dr. Stefano
Rivella, Professor
of Pediatrics and Ohene-Frempong Chair on Sickle Cell Anemia
at The Children's Hospital of Philadelphia, will lead the research
program.


"We are thrilled to collaborate with Dr. Rivella and his team to

Related Quotes

MDGN
6.14
+0.16%

Medgenics, Inc.
6.14 +0.01 (0.16%)
AMEX 11:24 AM EST

Watchlist



[Wayne gene therapy firm renews CHOP research partnership](#)

American City Business Journals 23 hrs ago

[MEDGENICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S](#)

EDGAR Online 1 day 2 hrs ago

[More](#)

assess the capabilities of the Medgenics TARGT_{EPO} platform in this predictive preclinical model of beta thalassemia,” commented Garry Neil, Chief Scientific Officer of Medgenics. “The results of this work should be highly informative as we advance this program toward the clinic.”

Previous observations have demonstrated that there is an intimate correlation between iron metabolism, organ and serum iron levels and erythropoiesis. It has been further demonstrated that iron restriction can improve erythropoiesis. The intent of the research program will be to demonstrate the ability of TARGT_{EPO} to improve anemia and, concurrently, decrease iron overload. TARGT_{EPO} will be utilized, in combination with an iron reducing approach, in a preclinical mouse model of beta-thalassemia to assess (1) improvement in anemia in NTD, (2) reduction in the need for blood transfusions in TDT, and (3) the ability to reduce or potentially prevent or reverse iron overload in both NTD and TDT.

About Medgenics, Inc.

Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the Company's website at www.medgenics.com.

Contact:

Contacts:

Medgenics, Inc.
John Leaman
john.leaman@medgenics.com

Brian Piper
Brian.piper@medgenics.com

Stern Investor Relations
Beth DelGiaccio
212-362-1200
Beth@sternir.com